P=N/A, N=114, Recruiting, Guy's and St Thomas' NHS Foundation Trust | Not yet recruiting --> Recruiting

Screening for drugs also revealed AKT1, TP53, and PIK3R4 as druggable hubs, and many drugs (e.g., Everolimus, Dabrafenib, Trabectedin) showing high-affinity interactions. The study discovers new prognostic markers (ATG4A, GABARAPL2, GAPDH) and druggable targets, which could lead to better risk stratification and smarter drug repurposing. While restricted to in silico analyses, the integrative approach provides a basis for subsequent laboratory confirmation and translational development.

P2, N=102, Active, not recruiting, Oregon Health and Science University | Trial completion date: Mar 2026 --> Oct 2026

P4, N=148, Recruiting, University of Louisville | Not yet recruiting --> Recruiting

P2, N=138, Completed, National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting --> Completed

P=N/A, N=49, Army Medical Center of PLA; Army Medical Center of PLA

Here we provide the basis for further development of trabectedin/irinotecan for patients with ES by the international cooperative groups. ClinicalTrials.gov: NCT04067115 .

P=N/A, N=13, Completed, West Virginia University | Recruiting --> Completed | N=20 --> 13

P2, N=271, Active, not recruiting, Boston University | Recruiting --> Active, not recruiting

P=N/A, N=224, Recruiting, The First Affiliated Hospital of Soochow University

P2, N=16, Recruiting, Italian Sarcoma Group | Trial primary completion date: Dec 2025 --> Dec 2026

Sub-cohorts included patients receiving neoadjuvant therapy (n = 33), primary resection (n = 193), palliative first-line chemotherapy (n = 26), or a palliative salvage therapy with trabectedin (n = 22)...SLFN11 is a prognostic and potentially predictive biomarker in STS in the context of chemotherapy. Our results support a prospective validation, standardization of SLFN11 assessment, and consecutive clinical implementation.